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A R T I C L E  I N F O A B S T R A C T
Since a large proportion of medical decisions are 
based on laboratory results, clinical laboratories 
should meet the increasing demand of clinicians and 
their patients. Huge central laboratories may pro-
cess over 10 million tests annually; they act as pro-
duction factories, measuring emergency and routine 
tests with sufficient speed and accuracy. At the same 
time, they also serve as specialized diagnostic cen-
ters where well-trained experts analyze and inter-
pret special test results. It is essential to improve and 
constantly monitor this complex laboratory service, 
by several methods. Sample transport by pneumatic 
tube system, use of an advanced laboratory informa-
tion system and point-of-care testing may result in 
decreased total turnaround time. The optimization 
of test ordering may result in a faster and more cost-
effective laboratory service. Autovalidation can save 
time for laboratory specialists, when the analysis of 
more complex results requires their attention. Small 
teams of experts responsible for special diagnostic 
work, and their interpretative reporting according to 
predetermined principles, may help to minimize sub-
jectivity of these special reports. Although laboratory 
investigations have become so diversely developed in 
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the past decades, it is essential that the labo-
ratory can provide accurate results relatively 
quickly, and that laboratory specialists can sup-
port the diagnosis and monitoring of patients 
by adequate interpretation of esoteric labora-
tory methods.

INTRODUCTION
Since about 2/3rd of medical decisions are 
based on laboratory test results (1), it is obvi-
ous that clinical laboratories need to be or-
ganized in the best possible way to meet this 
demand. Optimizing, in the economic aspect, 
usually means fusing smaller units into larger 
ones to save costs, as well as trying to auto-
mate as much as possible. Undoubtedly, this 
has been an ongoing tendency for decades and 
has resulted in centralized, mega-laboratories 
that may process 15-20 million tests per year. 
There are two key concepts in these large labo-
ratories: integration, where analytical instru-
ments or groups of instruments are linked with 
pre- and post-analytical devices, and consolida-
tion, where different analytical technologies or 
strategies are combined in one instrument or 
in a group of connected instruments. However, 
there is a logical limit to centralization, since no 
laboratory expert anticipates that a dozen ’ul-
tra-mega-large’ laboratories would be enough 
for a mid-size european country, or that these 
laboratories would be the best from the point 
of view of optimal patient care. Politicians and 
health economists, on the other hand, often 
tend to think differently, and, as they are un-
aware of the details of the laboratory profess-
sion, such conceptions may actually prevail. 
The majority of the laboratory tests are basic 
clinical chemistry, hematology, urinalysis and 
hemostasis screening tests. In many smaller lab-
oratories this comprises the whole repertoire of 
the laboratory. There are two expectations from 
the patients and their caretaking doctors: the 
results should be accurate and they should be 
delivered fast. The laboratories are putting a lot 
of effort in the former by using internal and ex-
ternal controls, investigating interfering factors 
and linearity values, however laboratories are 
sometimes not paying enough attention to de-
livering the results on time. The timely delivery 
of laboratory results, however, is also very im-
portant. It may become unnoticed by the doc-
tor if the laboratory is underestimating an en-
zyme activity by 10%, but the clinician probably 
does not accept if the same result is delayed by 
a few hours.
METHODS TO IMPROVE 
LABORATORY PERFORMANCE
The measuring clock of clinicians’ 
satisfaction: turnaround time 
Thus, each laboratory should monitor this key 
’satisfaction factor’ entitled turnaround time 
(TAT) and try to improve it as much as possible 
(2-5). One way for improvement is to modernize 
courier services in hospitals. The past years have 
proved that this is best achieved by automated 
transportation systems, the most widely used 
method being the pneumatic tube system. In 
these long tube systems that may reach a com-
plete length of over 20 kilometers, numerous 
compressors are utilized that produce the pres-
sure for independent circuits, which transport 
the capsules containing the laboratory samples. 
In the advanced systems, automated capsules 
are used, i.e. the capsule itself does not appear 
in the laboratory, but after its content is auto-
matically unloaded, it returns to the station of 
origin by the aid of a radiofrequency tag that is 
attached to the surface of the capsule. Such sys-
tems can also optimize the travelling speed of 
the capsule as being faster when the capsule is 
empty and slower when it is carrying a sample 
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(6 m/s versus 3 m/s) (6).  Another way to de-
crease TAT is to deploy laboratory testing to the 
actual site of patient care in the form of point of 
care testing (POCT). All POCT results, however, 
should be registered in the laboratory informa-
tion system (LIS) and only results that are ap-
propriately controlled, registered and validated 
should be used in patient care. (7)
Central laboratories usually have three 
types of assays based on TAT:
• Emergency testing. Here the complete ’from 
vein to brain’ TAT should be below 60 min-
utes. In some cases, extra-urgent samples 
may need to be further prioritized, such as 
in the case of patients with ischaemic stroke 
waiting for thrombolysis.
• Routine testing. The TAT for routine test re-
sults today may be quite close to the emer-
gency results, but a more realistic maximal 
routine TAT value is 3 hours. Nevertheless 
the median TAT for most the routine assays 
is around 80-90 minutes.
• Special testing. The TAT for these assays may 
be highly variable ranging from 2-20 working 
days. It can be assumed that no laboratory 
test should take more than 20 working days, 
as it would not be possible to effectively im-
plement those slowly generated results into 
actual patient care.
The first two types of testing are usually part of 
the ’production factory’ (8) while special testing 
occurs in specialized centers. A delicate balanc-
ing is required to devote sufficient resources 
from the laboratory to each of these test groups. 
Ways to optimize test ordering
While we provide a medical service for the pa-
tients, whether we like it or not, with a large 
part of laboratory testing we implement a 
factory-type work flow, mostly for bulk tests 
described above (9). It may be assumed that, 
indeed, doctors often use too many diagnostic 
tests, and these tests are requested too fre-
quently. This may be because they have erro-
neous expectations of the tests, are unaware of 
tests carried out previously, or are simply trying 
to be rigorous. Because these tests can be easily 
requested, it has been estimated that 8-30% of 
test requests may be superfluous (10). Thus, it is 
plausible that laboratory performance may also 
be improved by eliminating overtesting. This is, 
however, somewhat difficult to carry out opti-
mally, and several techniques have been sug-
gested to manage, or rather, to limit the order-
ing of test requests. One option is to allocate the 
whole laboratory budget to the requesters or 
to use a computerized clinical decision support 
system (CDSS) in medication as well as labora-
tory test ordering. Most other possibilities refer 
to tricks that the laboratory can do to prevent 
overtesting. These may include discouraging 
or not automatically fulfilling test requests, or 
creating explorative and reflective testing, such 
as beginning with a nonspecific, cost-effective 
but sensitive test, and then performing more 
targeted and usually more expensive tests only 
when the results of the initial screening tests 
are abnormal. A quite useful method could be 
to exert influence through setup of request 
forms, or to reduce the availiability of testing 
at certain times. A relatively low percentage of 
superfluous tests can also be eliminated by the 
laboratory through barring tests on predeter-
mined principles of frequency filtering (11). 
How to make the most  
of the laboratorians’ time: autovalidate
One way to achieve meaningful organization is 
by automated evaluation of laboratory results 
for straightforward cases using autovalidation. 
If a laboratory is not using autovalidation in 
2016, it is frustrating for the laboratory special-
ists, who are under constant pressure to devote 
their skills to checking the correctness of tens 
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of thousands of numerical values for ’simple 
cases’, which may belong to any of the groups 
below:
i. each laboratory result is within the age spe-
cific reference range;
ii. only minor, clinically insignificant laboratory 
changes occur or
iii. many laboratory results are pathological, 
but all are similar to preceding values and 
are compatible with the diagnosis provided.
Tedious manual validation of simple cases by 
laboratory specialists carries the risk of serial 
mistakes, since after a while it is impossible to 
responsibly evaluate large quantities of data. 
Additionally, this laborious task takes the expert 
laboratorian’s attention away from quality vali-
dation, where their time should be devoted to 
more complex cases.
In a large laboratory with a wide portfolio, the 
following simple rule may apply:
• Around 90% of the samples require 10% at-
tention and 
• The remaining 10% of the samples require 
90% attention.
REPORTING AND INTERPRETATION 
OF SPECIAL LABORATORY RESULTS
Expert opinion of simple tests
Now, what are those ’more complex’ cases that 
require considerably more time than a handful 
of ’simple cases’?
If we just consider the basic laboratory portfo-
lio, several complex cases could be mentioned. 
The automated hematology analyzer reports 
should be confirmed and validated, since false-
ly low neutrophil percentage may be reported 
with erroneously high monocyte numbers in 
cases with partial or complete myeloperoxidase 
(MPO) deficiency (12) if differential counts are 
based on volume and MPO activity (Figure 1A). 
In the case of unexpectedly high creatine kinase 
activity, further testing may be required to verify 
the presence of type I and type II macro-CK iso-
enzymes, an entity that results in falsely elevat-
ed CK-MB values in the immunoinhibition test 
Figure 1 Production factory: cases when more attention is needed  
in the routine laboratory
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(Figure 1B). Similarly, a clinically silent hemoglo-
bin variant, like the rare Hemoglobin Sherwood, 
can cause an extremely high value in the auto-
mated HPLC testing for glycated hemoglobin, 
where the diagnosis is provided by mutation 
analysis (Figure 1C). In addition to such cases 
several other areas exist that require interpre-
tative reports (13) that has been shown to con-
tribute to physician satisfaction (14). Aside from 
such cases, most of the quality time for general 
(A) Myeloperoxidase deficiency results in decreased ratio of neutrophiles, and elevated ratio of monocytes and large 
unstained cells (LUC) when the sample is measured on hematological analyzer using myeloperoxidase staining. 
(B) Macro CK results in high CK activity and disturbs the measurement of CK-MB activity using immunoinhibition 
method. On the CK electropherogram either macro CK 1 (red continuous arrow; patient 1), or macro CK 2 (red dotted 
arrow; patient 2) are shown compared to control (black arrows). 
(C) Extremely elevated hemoglobin A1c concentrations can be measured by HPLC in the presence of some rare 
hemoglobin variants (e.g. Sherwood forest hemoglobin variant).
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routine analysis is devoted to microscopic inves-
tigations of peripheral blood or cerebrospinal 
fluid samples.
Expert opinion of special tests
Another area of interpretative reporting is 
when samples are sent for more esoteric tests, 
and in many cases no test requests are indicat-
ed, rather, a hypothesized diagnosis need to be 
confirmed or rejected. 
These types of investigations mostly, but not 
exclusively, involve flow cytometric analysis of 
peripheral blood or bone marrow, cytogenetic 
analysis for G-banding or FISH, autoantibody 
pattern description, dynamic endocrine tests 
and special hemostasis assays for bleeding 
diathesis or thrombosis. Many of the nucleic 
acid-based tests can now be easily set up, but 
in some cases whole-genome sequencing and 
the interpretation of rare mutations may take 
many hours, or even days of qualified work 
from the laboratory specialists to delineate the 
diagnosis. Many of these techniques also re-
quire months or years of experience/training 
to gain sufficient expertise. Morphological skills 
are essential to evaluate pathological periph-
eral blood, bone-marrow or cerebrospinal fluid 
samples, or to describe autoantibody stain-
ing patterns. However, sometimes these skills 
become additional to other specialized skills, 
such as the ability to confidently read DNA 
sequencing curves, operate the software for 
flow cytometric dot plot analysis, or learn the 
details of a karyotyping software operation. It 
is also imperative to sustain the TAT concept in 
the case of these special tests. This means such 
a service cannot rely on a single expert, thus a 
minimum team of two people should handle 
the reports in each of these subspecialities. The 
best scenario, however, is a team of about three 
experts who take turns writing the reports 
while sticking to predetermined principles of 
data reporting to minimize subjectivity of these 
special reports. In our Department, the Divisons 
that exert the highest time-demand for special 
diagnostic work are summarized in Table 1. In 
all of these Divisions, a minimum of 3-5 special-
ists take turns reporting, and in some areas, two 
people are required for one type of subspecial-
ity for parallel reporting. 
These reports have a generally accepted format 
and the result sheet should include consider-
ably more data than a general chemistry assay.
A typical request of clinical flow cytometry for 
the investigation of hematological malignancies 
should include the followings (15):
• demographic identification of patient; 
• identification of the hospital or division send-
ing the sample; 
Special divisions with the 
highest time-demand of 
diagnostic work
Special diagnostic 
work 
(hours/week)
Annual interpreta-
tive reports (and its 
ratio of reports of 
division)
Turnaround time 
(working days)
Flow cytometry 70-80 3 000 (67%) 3
Molecular genetics 50-60 2 400 (33%) 12-20
Laboratory immunology 50-60 1 200 (5%) 10-20
Table 1 Special diagnostic work with the highest time - demand  
in the Department of  Laboratory Medicine at the University of  Debrecen
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• type of specimen (bone marrow aspirate, pe-
ripheral blood, other biological fluids);
• timing of observation (first sample or 
follow-up); 
• diagnostic hypothesis of the sender.
When reporting the results of the flow cytomet-
ric analysis, the following elements are required 
(15):
• list of antigens and type of immunofluores-
cence analysis;
• absolute number of cells in the sample;
• quality of the sample, in terms of viability;
• general description of the gating procedure;
• immunophenotype of blast cells;
• description of cells surrounding blasts;
• diagnostic conclusions.
In special cases, other parameters may be re-
quired, like the definition of an antigen panel 
for the detection of minimal residual disease. In 
addition, a representative dot plot is also part 
of the interpretative report. These attributes 
minimize the subjectivity of the special reports. 
Nevertheless, there are several flow cytometric 
analyses that do not require interpretative re-
porting. This usually depends on the question 
raised, when reporting of a sheer number is 
sufficient, like in the case of CD34 positive cell 
count, or when a qualitative answer is required, 
like in the flow cytometric heparin-induced 
thrombocytopenia assay.
Another example is genetic test reports that un-
doubtedly carry a serious clinical implication for 
prediction of susceptibility to disease, patient 
diagnosis, prognosis, counselling, treatment or 
family planning. Therefore, such laboratory re-
ports should provide a clear, concise, accurate, 
fully interpretative and authoritative answer to 
the clinical question (16).  
These reports should include a clearly structured 
format, comprised of the following information:
• administrative;
• patient and sample identification;
• restatement of the clinical question;
• specification of genetic tests used;
• results;
• interpretation of results.
Upon interpreting the results, the expert draws 
a conclusion that should contain any of the five 
subsequent possibilities: 
• normal finding(s);
• non-specific finding(s) without clinical 
relevance; 
• incidental finding(s) with possible clinical 
relevance;
• finding(s) of uncertain significance;
• pathognomonic (disease-specific, pathologi-
cal) finding(s).
When a new diagnosis is made based on these 
reports, it is appropriate to state specifically 
that the result has ‘potentially important impli-
cations for other family members’. Depending 
on the context, it may be appropriate to explic-
itly mention the recommendation to test the 
partner, the possibility of cascade screening 
tests in relatives, and the possibility of prenatal 
diagnosis or preimplantation genetic diagnosis. 
Genetic testing is unique in the respect that 
when appropriate, the risk for future offspring 
should be calculated and provided.
Several other areas of laboratory medicine exist 
where interpretative reports are required. One 
such area is autoantibody testing. In these stud-
ies, two or more methods are frequently used 
to identify an antibody marker and sometimes 
the results disagree. When this happens, an in-
terpretation is always required, specifying the 
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diagnostic accuracy of the tests. Similar to the 
previously described genetic tests, some au-
toantibodies that are not requested, and con-
sequently not expected, may be identified by 
chance. Such cases should only be interpreted 
when these antibodies have a significant clinical 
correlation (17). Examples from our laboratory 
are provided for interpretative flow cytometric, 
genetic and autoantibody reports in Figure 2.
Since laboratory tests are usually requested by 
well-trained clinicians who are aware of the 
diagnostic, prognostic and monitoring value 
of the results, the over-interpretation of self-
explanatory numerical tests can be useless and 
Figure 2 Specialized diagnostic centers: interpretation of  special laboratory results
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harmful. However, laboratory investigations 
have become so diversely developed in the past 
decades that in the aforementioned cases, as 
well as in case of many other special tests, it is 
essential that the laboratory specialist provides 
a meaningful interpretation to the laboratory 
findings.
CONCLUSION
A clinical laboratory should be organized in a 
way so that the clinical pathologist can utilize 
most of his/her trained skills in evaluating re-
sults of specialized diagnostic areas and in in-
terpreting laboratory reports for the physicians. 
This can be best achieved by introducing auto-
mated evaluation in the form of autovalidation 
in several routine laboratory fields in case of 
numerous samples that do not require direct 
medical surveillance. All these measures would 
facilitate that the laboratorian will become an 
indispensable part of the medical team.
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